Foghorn Therapeutics

Foghorn Therapeutics

  • Founded: 2016
  • Location: Cambridge, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin1
  • Therapy area: Uveal melanoma
  • Drug types: ONC
  • Lead product: FHD-286
  • Product link:
  • Funding: $120M IPO Oct 2020; $50M Mar 2018

job board

Short description:

Cancer Drug Discovery, Protein Degradation

Drug notes:

Also Clin1 AML; FHD-609 Clin1 synovial sarcoma; 9 undisclosed programs Clin0 oncology, undisclosed; undisclosed programs RD undisclosed

Long description:

Foghorn Therapeutics’ Gene Traffic Control platform is designed to target and modulate the chromatin regulatory system. Components of the chromatin regulatory system are synthesized and used for proprietary assays to guide the discovery and optimization of drug targets. High throughput screening of candidate compounds is then used to discover drugs that modulate the chromatin regulatory system. Foghorn currently has multiple therapeutics targeting cancer in Phase 1 clinical trials in addition to therapeutics targeting transcription factors and synthetic lethal targets, among others, in discovery stages. Phase 1 trials are currently enrolling for uveal melanoma, synovial sarcoma, acute myeloid leukemia, and myelodysplastic syndrome.


Foghorn Therapeutics
Associate Director of Financial Planning & Analysi...
Cambridge, Massachusetts|31 days ago
Foghorn Therapeutics
Director, Medicinal Chemistry
Cambridge, Massachusetts|51 days ago
Foghorn Therapeutics
Principal Scientist, Medicinal Chemistry
Cambridge, Massachusetts|52 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy